Custom Health Holdings Inc. to Commence Trading on the Toronto Stock Exchange

TSX listing and big financings, but no proof yet of business traction or profitability.

What the company is saying

Custom Health Holdings Inc. is positioning its TSX listing as a transformative milestone, aiming to convince investors that this move will elevate its profile and unlock new growth opportunities. The company’s narrative centers on the successful completion of its plan of arrangement with Custom Health, Inc. (Custom Delaware), emphasizing 100% ownership and the consolidation of assets. Management highlights the breadth and scale of its new financing arrangements—multiple credit facilities, convertible notes, and promissory notes totaling tens of millions of dollars—framing these as evidence of institutional confidence and future expansion capacity. The announcement repeatedly stresses the company’s transition from a 'venture issuer' to a full TSX-listed entity, suggesting this status will attract more sophisticated investors and improve access to capital. However, the language used to describe the benefits of the listing and financings is aspirational, with phrases like 'strengthen its capital markets presence' and 'support long-term strategic objectives' left undefined and unsupported by operational metrics. The company is explicit about the mechanics of its financings—interest rates, maturities, warrant coverage—but omits any discussion of current revenues, profitability, or customer traction. The tone is upbeat and confident, projecting momentum and institutional validation, but avoids addressing execution risks or the company’s underlying business fundamentals. Notable individuals named include Shane Bishop (CEO) and Pardeep Sangha (Investor Relations), but there is no mention of high-profile external investors or strategic partners, which limits the implied third-party endorsement. Overall, the messaging fits a classic pre-commercial or early-stage growth company playbook: focus on capital markets milestones and funding, while deferring hard questions about business performance.

What the data suggests

The disclosed numbers are detailed regarding the structure and terms of the company’s new financings, but provide no insight into operational or financial performance. Specifically, the company has secured up to US$20 million in senior secured convertible notes (Funicular Notes), up to US$15 million in promissory notes (Yorkville), and up to US$15 million in unsecured convertible promissory notes (102 Saskatchewan Notes), alongside a C$7 million senior secured credit facility and a C$3 million revolving credit facility with Fair Capital Partners Inc. The 102 Saskatchewan Notes carry a 12% annual interest rate and mature 18 months post-listing, with a 9.99% beneficial ownership cap, indicating a relatively high cost of capital and some lender caution. Warrant coverage is substantial, with Funicular Warrants covering 50% of the note principal and Yorkville Warrants covering 100% of the first tranche, both with exercise prices set at a premium to recent trading averages or a floor of US$8.00. The company has issued a US$3 million promissory note to YA II PN, Ltd. as the initial lender, but there is no disclosure of how much of the remaining facilities have been drawn or committed. Critically, there are no revenue, EBITDA, net income, or cash flow figures disclosed—no period-over-period financials, no growth rates, and no operational KPIs. This means investors cannot assess whether the company is growing, shrinking, or even generating meaningful revenue. The only financial direction implied is aggressive capital raising, not business performance. An independent analyst would conclude that while the company has successfully arranged significant financing, the absence of any operational or financial results is a major red flag for diligence. The disclosures are thorough on debt and warrant mechanics, but incomplete on the fundamentals that drive long-term value.

Analysis

The announcement is positive in tone, highlighting the TSX listing approval and the completion of several financing arrangements. Most key claims are realised and supported by executed agreements, such as the listing approval, acquisition completion, and signed credit facilities. However, the narrative inflates the significance of the listing by projecting that it will 'strengthen its capital markets presence and support long-term strategic objectives'—a forward-looking claim with no measurable evidence or timeline. The benefits of the large capital outlays (multiple facilities and notes totaling tens of millions) are not quantified in terms of operational or financial impact, and there is no disclosure of revenue, EBITDA, or customer traction. The forward-looking statements section contains several aspirational projections about future trading, relationships, and financing access, but these are not the majority of the announcement. The gap between narrative and evidence is moderate: while the financing and listing are real, the strategic benefits and long-term value creation remain unsubstantiated.

Risk flags

• ●Operational risk is high because the company provides no evidence of current revenue, profitability, or customer traction. Without these metrics, investors cannot assess whether the business model is viable or scalable.
• ●Financial risk is elevated due to the large volume of new debt and convertible notes—over US$50 million in aggregate principal—without any disclosure of cash flow or repayment capacity. High interest rates (e.g., 12% on the 102 Saskatchewan Notes) further increase the burden.
• ●Disclosure risk is significant: the announcement omits all operational and financial performance data, making it impossible to evaluate the company’s underlying health or growth trajectory. This lack of transparency is a major concern for investors seeking to understand risk-adjusted returns.
• ●Pattern-based risk is present in the company’s focus on capital markets milestones (listing, financings) rather than business fundamentals. This is a common pattern among early-stage or pre-commercial companies that may struggle to deliver on growth promises.
• ●Timeline/execution risk is substantial, as most of the claimed benefits are forward-looking and will not be testable for at least 12-18 months. If the company fails to execute or market conditions deteriorate, the promised value may never materialize.
• ●Capital intensity risk is flagged by the sheer scale of the financings relative to the absence of disclosed revenue or cash flow. High capital requirements with distant or uncertain payoff are a classic warning sign for dilution or future refinancing needs.
• ●Geographic and regulatory risk is implied by the company’s operations spanning British Columbia, Alberta, and the United States, but there is no detail on how regulatory differences or cross-border complexities are being managed. This could impact execution and compliance costs.
• ●Management risk is moderate: while the CEO and IR contact are named, there is no mention of high-profile external investors, strategic partners, or board members with a track record of value creation in similar businesses. This limits external validation and increases reliance on internal execution.

Bottom line

For investors, this announcement is primarily a capital markets event: Custom Health Holdings Inc. has secured a TSX listing and lined up substantial new debt and credit facilities, but has not provided any evidence of business traction, revenue, or profitability. The company’s narrative is credible only insofar as the financings and listing are real and executed, but the leap from capital raised to value creation is entirely unproven. The absence of operational or financial performance data is a glaring omission—without it, investors are being asked to take management’s growth story on faith. The presence of named management (CEO Shane Bishop, IR Pardeep Sangha) is standard, but there are no notable institutional investors or strategic partners to provide third-party validation or signal future deal flow. To change this assessment, the company would need to disclose concrete metrics: revenue growth, customer wins, EBITDA improvement, or evidence that the new capital is driving measurable business outcomes. In the next reporting period, investors should watch for any operational KPIs, cash flow statements, or updates on how much of the financing has actually been drawn and deployed. At this stage, the information is worth monitoring but not acting on—there is not enough substance to justify a new investment or a material portfolio allocation. The single most important takeaway: until Custom Health demonstrates real business progress, the TSX listing and financings are necessary but not sufficient conditions for long-term value creation.

Announcement summary

(TSX: CHLT) Custom Health Holdings Inc. announced that it has received final approval for listing on the Toronto Stock Exchange, with its common shares set to commence trading under the symbol "CHLT" at market open on June 24, 2026. The company completed a plan of arrangement with Custom Health, Inc. (Custom Delaware), acquiring 100% of the issued and outstanding common stock of Custom Delaware. Custom Health has entered into several financing arrangements, including senior secured convertible notes with an aggregate principal amount of up to US$20,000, promissory notes in an aggregate principal amount of up to US$15,000, and unsecured convertible promissory notes in an aggregate principal amount of up to US$15,000,000. The company also established a senior secured credit facility of C$7,000,000 and a revolving credit facility of C$3,000,000 with Fair Capital Partners Inc. The 102 Saskatchewan Notes bear an interest rate of 12% per annum, have a maturity of 18 months following the Listing, and are subject to a 9.99% beneficial ownership cap. The company reports that it is no longer a "venture issuer" as defined in NI 51-102. The company projects that the listing on the TSX will strengthen its capital markets presence and support long-term strategic objectives.

Disagree with this article?